以博安霉素为主的新方案治疗难治性非霍奇金淋巴瘤的疗效观察

Efficacy observation on the treatment of a novel regimen based on boanmycin for patients with refractory non-Hodgkin lymphoma

目的观察以博安霉素为主的新方案治疗化疗后肿瘤反弹较快而骨髓造血功能较差的复发难治性非霍奇金淋巴瘤（NHL）患者的疗效和不良反应。方法采用新组合的B—VIP方案博安霉素8．73mg静脉滴注第1、4、8、12、15天，长春新碱（VCR）2mg静脉滴注第1、8、15天，异环磷酰胺（IFO）每天1．2g／m。静脉滴注第1天至第3天、第15天至第17天，泼尼松50mg口服第1天至第10天，21d为1个疗程1治疗常规方案治疗无效或难以耐受的复发难治性NHL6例，该组患者此前已用其他方案化疗平均8．3个周期。结果6例均可评价疗效和不良反应，总有效4例，完全缓解（CR）1例，部分缓解（PR）3例。主要不良反应为骨髓抑制，其他不良反应较少。结论B—VIP方案是常规方案治疗无效或难以耐受标准化疗而肿瘤进展较快的复发难治性NHL的有效方案，毒性较低，较为经济。

Objective To observe the activity and safety of a novel combination therapy for patients with recurrent or refractory aggressive non-Hodgkin lymphoma （NHL）. Methods Six consecutive patients with recurrent or refractory aggressive NHL were treated with B-VIP regimen, boanmycin （5 mg/m2 on Days 1, 4, 8, 12 and 15）, vincristine （1.4 rag/mE on Days 1, 8 and 15）, ifosfamide （1.2 g/m2 on Days 1, 2, 3 and 15, 16, 17） and prednisone （50 mg on Days 1 to 10）, every 21 days. All the patients had received /〉5 cycles （average 8.3 cycles） of previous chemotherapy. Results Six patients （100 %） were evaluable for response. The overall objective response rate was 66.7 % （4 patients）, including 1 case complete （CR） and 3 cases partial responses. Myelosuppression was the most frequent serious complication of this regimen. Conclusion In the current study, B-VIP was a highly active and safe combination therapy for patients with refractory disease with a poor prognosis or for patients with multiply recurrent aggressive NHL.